

CHAMPIONS ONCOLOGY, INC.
Form 4
March 23, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
ACKERMAN JOEL

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC.
[CSBR]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
03/16/2015

Director 10% Owner
 Officer (give title below) Other (specify below)
Chief Executive Officer

C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLACE, SUITE 307

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

HACKENSACK, NJ 07601

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CHAMPIONS ONCOLOGY, INC. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Option to purchase Common Stock	\$ 0.41	03/16/2015		A		2,190,958		<u>(1)</u>	10/25/2020	Common Stock	2,190,958
Option to purchase Common Stock	\$ 0.41	03/16/2015		A		2,190,959		<u>(2)</u>	10/25/2020	Common Stock	2,190,959
Option to purchase Common Stock	\$ 0.41	03/16/2015		A		1,347,977		<u>(3)</u>	11/05/2013	Common Stock	1,347,977
Option to purchase Common Stock	\$ 0.41	03/16/2015		A		1,347,977		<u>(4)</u>	11/05/2013	Common Stock	1,347,977
Option to purchase Common Stock	\$ 0.41	03/16/2015		A		193,210		<u>(5)</u>	11/05/2013	Common Stock	193,210
Option to purchase Common Stock	\$ 0.41	03/16/2015		A		1,155,400		<u>(6)</u>	03/16/2015	Common Stock	1,155,400

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ACKERMAN JOEL C/O CHAMPIONS ONCOLOGY, INC. ONE UNIVERSITY PLACE, SUITE 307 HACKENSACK, NJ 07601	X		Chief Executive Officer	

Signatures

/s/ Joel Ackerman 03/23/2015

Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Fully vested upon grant.
- (2) Fully vested upon grant.
- (3) Vested as to 561,655 shares on grant; remainder vests quarterly over period ending on November 4, 2016, with the next vesting to occur on May 5, 2015.
- (4) Vesting to occur upon completion of performance criteria that have not been set.
- (5) Fully vested upon grant.
- (6) Vested as to 288,850 shares on grant; remainder vests quarterly over period ending on November 4, 2015, with the next vesting to occur on May 5, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.